Main Article Content
Abstract
Chronic kidney disease (CKD) is a common disorder that results in severe morbidity and mortality. Dyslipidemia is a common CKD consequence that causes changes in lipid metabolism and increases the risk of cardiovascular disease (CVD). The efficacy and safety of CKD patients are still being debated because to concerns about potential side effects and changed pharmacokinetics in this population. Current CKD management may have an impact on lipid levels as well. This describes the modifications made to both hemodialysis and peritoneal dialysis in CKD patients. Statin medication is an important consideration in the treatment of dyslipidemia in CKD patients. Niacin and fibrates are effective lipid-lowering agents in CKD and appear to have some cardiovascular advantages. Nephrotic syndrome causes hyperlipidemia and significant changes in lipid and lipoprotein metabolism. The review summarises current information on the roles of lipids in CKD patients, providing an overview of lipoprotein metabolism, emphasising CKD-induced changes and the safety impact of Statin medication on CKD patients.